logo

ARCT

Arcturus Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.54 / 10
Netural

ARCT's fundamental score is 4.5/10, indicating a balanced but not outstanding profile. Key positives include a Days sales outstanding of 21.51 (ranked in group 1, quality score 2/3) and an Interest coverage ratio of 15.48 (group 1, quality score 2). However, both Total operating revenue and Operating revenue show YoY declines of -42.23%, placing them in performance group 1 with limited historical returns. Other factors like Revenue-MV (-1.51) and Asset-MV (-0.50) are in groups 2 and 3 respectively, contributing to a moderate overall fundamental stance. The weighted score (4.54) reflects these mixed inputs, with PB-ROE and Asset-MV carrying the highest weights (0.1697 and 0.2584).

Fundamental(4.54)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-1.51
Score3/3
Weight17.48%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value-42.23
Score1/3
Weight-1.02%
1M Return-0.79%
Days sales outstanding
Value21.51
Score2/3
Weight1.52%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight13.94%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight13.95%
1M Return8.45%
PB-ROE
Value0.72
Score1/3
Weight16.97%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.39%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-42.23
Score1/3
Weight-0.98%
1M Return-0.76%
Asset-MV
Value-0.50
Score3/3
Weight25.84%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight13.70%
1M Return8.41%
Is ARCT fundamentally strong?
  • ARCT scores 4.54/10 on fundamentals and holds a Fair valuation at present. Backed by its -15.77% ROE, -68.35% net margin, -3.58 P/E ratio, 0.96 P/B ratio, and -5.58% earnings growth, these metrics solidify its Netural investment rating.